This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Zinforo® can be used to treat paediatric patients with cSSTI or CAP from birth1

Zinforo provides an early clinical response in paediatric patients with cSSTI2

Zinforo was as effective as comparator therapy in the treatment of paediatric patients aged 2 months to <18 years with cSSTI (N=159), including those caused by MRSA (n=18)*

Dosing:

  • ​​​​​​​Zinforo: Age- and weight-adjusted dosesinfused over 60 minutes every 8 hours 
  • Comparators: Vancomycin 15 mg/kg infused over ≥60 minutes every 6 hours (or a maximum of 10 mg/min, whichever was longer), or cefazolin 75 mg/kg/day divided and infused every 8 hours (plus optional aztreonam 30 mg/kg infused every 8 hours if a Gram-negative pathogen was identified or suspected) 
  • A switch to oral therapy with either cephalexin, clindamycin or linezolid (depending on pathogen susceptibility) after Day 3 was permitted 

Clinical cure rates at test-of-cure (MITT population) ​​​​​​​

Clinical response (cessation of spread measured by total length and width separately, and temperature ≤37.6°C) at Day 3 (MITT population) ​​​​​​​

Microbiological eradication by baseline pathogen

Zinforo provides favourable clinical outcomes in paediatric patients with CAP3

Zinforo had similar effectiveness to ceftriaxone in the treatment of paediatric patients aged 2 months to <18 years who were hospitalised with CAP (N=143)¶ 

Dosing: 

  • Zinforo: Age- and weight-adjusted doses every 8 hours 
  • Ceftriaxone: 75 mg/kg (up to 4 g/day) every 12 hours 
  • A switch to oral therapy with amoxicillin/clavulanate on Day 4 was permitted

 Clinical cure rates at test-of-cure (MITT population) 

Clinical response rates at Day 4 

Explore More

Zinforo has a proven tolerability profile in children of all ages, including neonates​​​​​​​2,3

The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.

Access tolerability profile

** This is an optional area where footnotes can live.


*Multicentre, randomised, observer-blinded, active-controlled study where the primary objective was to evaluate the safety and tolerability of Zinforo. The study was not powered for comparative inferential efficacy analysis, and no efficacy endpoint was identified as primary.
†Doses of Zinforo were based on paediatric population pharmacokinetic modelling designed to achieve the same antibiotic exposure in children that was shown to be effective in adults. 
‡Evaluated 8–15 days after the last dose of any antibiotic (IV or oral).
¶Multicentre, randomised, prospective, comparator-controlled study where the primary objective was to evaluate the safety and tolerability of Zinforo. The study was not powered for comparative inferential efficacy analysis, and no efficacy endpoint was identified as primary.
**Zinforo is not active against Pseudomonas aeruginosa. Like other cephalosporins, Zinforo is not active against ESBL-producing strains. In vitro activity does not always correlate with clinical efficacy.1
Abbreviations

CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; CE, clinically evaluable; TOC, test-of-cure; MITT, modified intent-to-treat; IV, intravenous; MRSA, methicillin-resistant Staphylococcus aureus. 
References
  1. ZINFORO. Summary of Product Characteristics
  2. Korczowski B, et al. Pediatr Infect Dis J 2016;35:e239–47
  3. Cannavino CR, et al. Pediatr Infect Dis J 2016;35:752–59
  4. Laudano JB. J Antimicrob Chemother 2011;66(Suppl.3):iii11-iii18
  5. Garrison MW, et al. Expert Rev Anti Infect Ther 2012;10:1087-103
  6. Drusano, GL. J Antimicrob Chemother 2011;66(Suppl3):iii61–7
PP-ZFO-GBR-0227. September 2021

Discover further specific information on the dosing regimen of Zinforo in neonates, infants and children here

Zinforo has an extended in vitro spectrum of coverage, including key pathogens in CAP and cSSTI**1,4-6

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No